| Objective: To explore the efficacy and mechanism of action in Jishengshenqi pill combine with dapagliflozin in the treatment of diabetes nephropathy (DN) based on NOD like receptor protein 3 (NLRP3) inflammatory corpuscles. Method: 140 DN patients were divided into control group (n=70, treated with dapagliflozin) and study group (n=70, treated with Jishengshenqi pill combine with dapagliflozin) used random number table. The TCM syndrome scores, blood glucose index, renal function index, peripheral blood NLRP3 levels, and related factor levels between two groups of patients were compared. Result: The scores of dysuria, fatigue and cold intolerance, edema, soreness and coldness in the waist and knees, abdominal distension, pale complexion and lower five shift diarrhea in the study group after treatment were lower than those in the control group (P<0.05). Fasting blood glucose (FBG), serum creatinine (SCr), 2-hour postprandial blood glucose (2hPG), blood urea nitrogen (BUN), hemoglobin A1c (HbA1c), NLRP3 messenger RNA (mRNA), and cysteine protease 1 (Caspase-1) levels in the study group after treatment were lower than those in the control group (P<0.05). Conclusion:After the treatment of Jishengshenqi pill combine with dapagliflozin in DN patients, the clinical symptoms and blood glucose can be effectively controlled, and renal function can also be improved, it is speculated that this is related to the inhibition of NLRP3 mRNA expression in peripheral blood mononuclear cells and the activation and amplification of downstream inflammatory pathways. |
